Genomic medicine: Predictors of refractory ulcerative colitis and its response to treatment

基因组医学：难治性溃疡性结肠炎的预测因素及其对治疗的反应

• 批准号: nhmrc : 1028569
• 负责人: A/Pr Graham Radford-Smith
• 金额: $ 58.61万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/genomic-medicine-predictors-response-treatment/110649
• 关键词: Genomic; medicine; Predictors; refractory; ulcerative

Ulcerative colitis (UC) is a major form of inflammatory bowel disease, affecting over 35,000 Australians. Symptoms include bleeding from the anus, tummy pain, and diarrhoea. There is a 1 in 4 risk of needing major surgery for UC. Our study will use current genetic techniques to classify patients according to the severity of their colitis, and their response to treatments. This will allow clinicians to personalize medical treatment far more effectively from the outset of a patients’ disease.

溃疡性结肠炎（UC）是炎症性肠病的主要形式，影响超过35，000名澳大利亚人。症状包括肛门出血、肚子痛和腹泻。UC需要大手术的风险为1/4。我们的研究将使用目前的遗传技术，根据结肠炎的严重程度和对治疗的反应对患者进行分类。这将使临床医生能够从患者疾病的一开始就更有效地进行个性化医疗。